Skip to content

Jazz Pharmaceuticals JAZZ Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$98.27M+32.3%
Summit Therapeutics logo
Summit TherapeuticsSMMT
-$189.52M-200%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
-$112.99M-35.0%
Biogen logo
BiogenBIIB
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Jazz Pharmaceuticals (JAZZ) reported comprehensive income (loss), net of tax, attributable to parent of $210.7M in Q1 2026.
How has Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent increased by 203.2% year-over-year, from $69.5M to $210.7M.
What is the long-term trend for Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2021 to 2025), Jazz Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a -80.4% compound annual growth rate (CAGR), from -$595.68M to $22.91M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
The total change in company value from non-operating sources like currency fluctuations and hedging.
How do you interpret comprehensive income (loss), net of tax, attributable to parent?
An increase indicates favorable movements in non-operating items like foreign exchange or derivatives, while a decrease suggests negative impacts from these external factors.
How does comprehensive income (loss), net of tax, attributable to parent compare across companies?
Common across all multinational corporations; peers often report this as OCI in the statement of comprehensive income.